TRiCares

TRiCares is a private, clinical-stage medical device company focused on revolutionizing the treatment of tricuspid regurgitation (TR) with its Topaz transcatheter valve replacement system. The company is actively conducting pivotal studies in the EU and an early feasibility study in the US, supported by substantial venture funding and a recent €20 million loan from the European Investment Bank. With a seasoned leadership team and a large, underserved patient population, TRiCares is positioning itself as a key player in the emerging transcatheter tricuspid intervention market.

Minimally invasive, catheter-based transcatheter tricuspid valve replacement (TTVR) system designed for implantation without open-heart surgery.

The transcatheter tricuspid intervention market is becoming increasingly competitive, with major players like Edwards Lifesciences (Evoque), Abbott (TriClip), and Medtronic (Intrepid, Pascal) advancing repair and replacement systems. TRiCares competes directly in the TTVR segment against companies like JC Medical (formerly Cardiovalve) and potentially others, where technical differentiation in valve design and delivery is critical.